全文获取类型
收费全文 | 1721篇 |
免费 | 190篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 145篇 |
妇产科学 | 27篇 |
基础医学 | 234篇 |
口腔科学 | 111篇 |
临床医学 | 169篇 |
内科学 | 324篇 |
皮肤病学 | 50篇 |
神经病学 | 37篇 |
特种医学 | 175篇 |
外科学 | 280篇 |
综合类 | 38篇 |
预防医学 | 114篇 |
眼科学 | 43篇 |
药学 | 61篇 |
中国医学 | 2篇 |
肿瘤学 | 123篇 |
出版年
2023年 | 15篇 |
2022年 | 13篇 |
2021年 | 21篇 |
2020年 | 15篇 |
2019年 | 14篇 |
2018年 | 50篇 |
2017年 | 49篇 |
2016年 | 46篇 |
2015年 | 68篇 |
2014年 | 82篇 |
2013年 | 115篇 |
2012年 | 64篇 |
2011年 | 45篇 |
2010年 | 88篇 |
2009年 | 95篇 |
2008年 | 49篇 |
2007年 | 60篇 |
2006年 | 59篇 |
2005年 | 29篇 |
2004年 | 39篇 |
2003年 | 28篇 |
2002年 | 23篇 |
2001年 | 19篇 |
2000年 | 16篇 |
1999年 | 29篇 |
1998年 | 102篇 |
1997年 | 88篇 |
1996年 | 99篇 |
1995年 | 64篇 |
1994年 | 74篇 |
1993年 | 39篇 |
1992年 | 15篇 |
1991年 | 26篇 |
1990年 | 14篇 |
1989年 | 33篇 |
1988年 | 34篇 |
1987年 | 28篇 |
1986年 | 26篇 |
1985年 | 25篇 |
1984年 | 12篇 |
1983年 | 11篇 |
1982年 | 26篇 |
1981年 | 17篇 |
1980年 | 23篇 |
1979年 | 6篇 |
1978年 | 8篇 |
1977年 | 9篇 |
1976年 | 13篇 |
1975年 | 9篇 |
1966年 | 1篇 |
排序方式: 共有1939条查询结果,搜索用时 15 毫秒
21.
22.
23.
R Dixon AM Hughes K Nairn M Sellers JV Kemp RA Yates 《Cephalalgia : an international journal of headache》1998,18(7):468-475
Zolmitriptan (ZomigTM ) is a 5HT1B/1D agonist which has the ability to cross the intact blood-brain barrier to access central as well as peripheral receptors. Because of the potential for central nervous system side effects, this randomized, double-blind, placebo-controlled, 6-period crossover study evaluated the effects of 2.5 and 5 mg doses of zolmitriptan on psychomotor performance and investigated any pharmacodynamic or pharmacokinetic interaction with diazepam. Twelve healthy volunteers received the following "treatments" as single doses: zolmitriptan 2.5 mg, zolmitriptan 5 mg, diazepam 10 mg, zolmitriptan 2.5 mg+diazepam 10 mg, zolmitriptan 5 mg+diazepam 10 mg and placebo. Pre-dose and at 1, 4, 8, and 24 h post-dose, the following validated battery of psychomotor tests was performed: Bond-Lader visual analogue scales (calmness, contentedness, and alertness factors), critical flicker fusion test, choice reaction time (recognition, motor, and total reaction times), finger-tapping test, number cancellation test and digit symbol substitution test. Plasma concentrations of zolmitriptan, its active metabolite, and diazepam and its active metabolites were measured at the same timepoints. Zolmitriptan 2.5 and 5 mg had no effect on psychomotor function when given alone. In contrast, diazepam 10 mg had profound effects, consistent with its sedative properties, but there was no synergism on concomitant administration of either dose of zolmitriptan. Plasma concentrations of zolmitriptan, diazepam, and their respective active metabolites were similar when the two drugs were given alone or in combination. 相似文献
24.
25.
26.
Mutations in the retinal guanylate cyclase (RETGC-1) gene in dominant cone-rod dystrophy 总被引:3,自引:0,他引:3
Kelsell RE; Gregory-Evans K; Payne AM; Perrault I; Kaplan J; Yang RB; Garbers DL; Bird AC; Moore AT; Hunt DM 《Human molecular genetics》1998,7(7):1179-1184
The dominant cone-rod dystrophy gene CORD6 has previously been mapped to
within an 8 cM interval on chromosome 17p12-p13. The retinal- specific
guanylate cyclase gene (RETGC-1), which maps to within this genetic
interval and previously was implicated in Leber's congenital amaurosis, was
screened for mutations within this family and in a panel of small families
and individuals with various cone and cone- rod dystrophy phenotypes. A
missense mutation (E837D) was identified in affected members of the CORD6
family, as well as a second missense mutation (R838C) in three other
families with dominant cone-rod dystrophy. RETGC-1 is only the fourth gene
to be implicated in cone-rod dystrophy and this is the first report of
dominant mutations in this gene.
相似文献
27.
Tommasi S Fedele V Crapolicchio A Bellizzi A Paradiso A Reshkin SJ 《International journal of molecular medicine》2003,12(1):131-134
The erbB2 gene is often found amplified and/or overexpressed in breast cancer in which it has clinical relevance as prognostic and predictive factor. It is involved in growth regulation and has a role in the initial phases of cell proliferation, while in vivo and in vitro studies have suggested an involvement also in cell invasion and metastases. It is not clear if these two roles are mutually exclusive and little is known about the mechanisms by which erbB2 may be involved in the control of these processes. Our previous data on patient series suggested that erbB2 might be regulated in different ways depending on the neoplastic status of the cells and that it might be involved in different regulatory pathways. To test this hypothesis we have measured the serum-dependent regulation of erbB2 as a function of the expression of the antimetastatic gene, nm23, in a panel of breast cancer cell lines. The experimental model consisted of three cell lines having different proliferative and invasive potentials: a non-metastatic estrogen receptor (ER) positive cell line, MCF-7; a highly metastatic ER negative cell line, MDA-MB435; and the MDA-MB435 cell line transfected with the nm23-H1 antimetastatic gene (clone H1-177) which has lost the ability to invade and metastasize. We first analysed the serum concentration dependence of invasion and proliferation after 3-4 days of serum deprivation confirming the proliferative and invasive potential of the three cell lines. Modulation of erbB2 expression by different concentrations of serum was then studied. ErbB2 expression in MCF-7 cells showed a complex pattern due to serum modulation, whereas, it was not longer regulated by serum in the MDA-MB435 cell line. In H1-177 cells the erbB2 response to serum was restored and it was very similar to that observed in MCF-7. These data showed a tight association between nm23 and the regulation of erbB2 expression by serum factors suggesting that the role of erbB2 in invasion might be dependent on nm23 expression. 相似文献
28.
Localization of a gene for otosclerosis to chromosome 15q25-q26 总被引:5,自引:0,他引:5
Tomek MS; Brown MR; Mani SR; Ramesh A; Srisailapathy CR; Coucke P; Zbar RI; Bell AM; McGuirt WT; Fukushima K; Willems PJ; Van Camp G; Smith RJ 《Human molecular genetics》1998,7(2):285-290
Among white adults otosclerosis is the single most common cause of hearing
impairment. Although the genetics of this disease are controversial, the
majority of studies indicate autosomal dominant inheritance with reduced
penetrance. We studied a large multi- generational family in which
otosclerosis has been inherited in an autosomal dominant pattern. Five of16
affected persons have surgically confirmed otosclerosis; the remaining nine
have a conductive hearing loss but have not undergone corrective surgery.
To locate the disease- causing gene we completed genetic linkage analysis
using short tandem repeat polymorphisms (STRPs) distributed over the entire
genome. Multipoint linkage analysis showed that only one genomic region, on
chromosome 15q, generated a lod score >2.0. Additional STRPs were typed
in this area, resulting in a lod score of 3.4. STRPs FES (centromeric) and
D15S657 (telomeric) flank the 14. 5 cM region that contains an otosclerosis
gene.
相似文献
29.
30.
Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women 总被引:1,自引:0,他引:1
Croxatto HB; Salvatierra AM; Fuentealba B; Massai R 《Human reproduction (Oxford, England)》1998,13(12):3297-3302
The effectiveness of a sequential regimen consisting of mifepristone, 10
mg/day for 15 days, followed by nomegestrol acetate (NOMA), 5 mg/day for
the next 13 days, for inhibiting ovulation and maintaining regular bleeding
cycles was assessed in 10 surgically sterilized volunteers who were
followed for one pretreatment and three treated cycles. Hormonal
determinations in blood and urine, ovarian ultrasonography, bleeding
records in all cycles and an endometrial biopsy taken on day 22-25 of the
third treatment cycle were used to monitor the effects of treatment. During
treatment, 24 monophasic (no sustained progesterone rise above 12 nmol/l)
and six biphasic cycles were recorded. Nine follicular ruptures were
detected echographically in these 30 treated cycles, five of which occurred
in monophasic cycles. All follicular ruptures occurred on days 1-7 of NOMA
treatment. Echographic and endocrine features of ovulatory cycles were both
present in only four treated cycles (13.3%). Development of a secretory
endometrium was achieved in all cases, but it was always irregular. Regular
withdrawal bleeding occurred in all subjects and no adverse reactions were
recorded. The ovarian and endometrial effects of this regimen justify
testing its contraceptive effectiveness in phase 2 clinical trials.
相似文献